This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Athersys Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	2.1yrs
Durata media del Consiglio di amministrazione	Nessun dato

Aggiornamenti recenti sulla gestione

Recent updates

One Analyst's Revenue Estimates For Athersys, Inc. (NASDAQ:ATHX) Are Surging Higher

Aug 16

Athersys stock falls ~9% after reporting Q2 loss, fall in cash and cash equivalents

Aug 12

Kasey Rosado named interim CFO of Athersys

Aug 04

Athersys: Dead Man Walking

Jul 25

Athersys: Focus On Stroke

May 04

Athersys - Hero Or Zero Opportunity

Apr 18

Athersys: Near-Term Progress In Stem Cell Phase 3 Trials Could Multiply Shares In 2022

Jan 20

Here's Why Athersys (NASDAQ:ATHX) Must Use Its Cash Wisely

Dec 30

Athersys: COVID-ARDS Is The Company's Most Important Target

Nov 25

Athersys Shares Are Ready To Rumble Following Period Of Turmoil

Aug 30

Athersys: Subgroup Analysis As A Masterstroke

Jul 29

Here's Why We're Watching Athersys' (NASDAQ:ATHX) Cash Burn Situation

May 28

Is Athersys (NASDAQ:ATHX) In A Good Position To Invest In Growth?

Feb 27

AMMINISTRATORE DELEGATO

Athersys non ha un CEO, o non abbiamo dati su di loro.

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Z. Rosado	Interim CFO & Director	2.1yrs	US$1.51m	Nessun dato
Senthil Ranganathan	Vice President of Technical Operations	1.7yrs	Nessun dato	Nessun dato
David Russ	Vice President of Supply Chain	1.7yrs	Nessun dato	Nessun dato
Manal Morsy	Executive VP & Head of Global Regulatory Affairs	11.7yrs	Nessun dato	Nessun dato
Robert Mays	Executive VP	8.2yrs	Nessun dato	Nessun dato
Rakesh Ramachandran	Head of Information Technology & Communications and VP	7.7yrs	Nessun dato	Nessun dato
Sarah Busch	VP of Regenerative Medicine & Head of Business Development	1.7yrs	Nessun dato	Nessun dato
Ellen Gurley	Manager of Corporate Communications and Investor Relations	no data	Nessun dato	Nessun dato

2.1yrs

Durata media

Gestione esperta: Il team dirigenziale di ATHX.Q è considerato esperto (durata media dell'incarico 2.1 anni).

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2024/09/25 11:24
Prezzo dell'azione a fine giornata	2024/09/25 00:00
Guadagni	2023/09/30
Guadagni annuali	2022/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Athersys, Inc. è coperta da 13 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
James Molloy	Alliance Global Partners
Gregory Harrison	BofA Global Research
Raymond Deacon	Brean Capital

This company listing is no longer active

Athersys Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Athersys, Inc. Announces Termination of Daniel A. Camardo as Chief Executive Officer, Effective from December 31, 2023

Athersys, Inc. Appoints Jane Wasman as Board Chair

Athersys, Inc. Appoints Neema Mayhugh to Its Board of Directors, Nominations, Governance and Compliance Committee, Compensation Committee and Audit Committee

Athersys, Inc., Annual General Meeting, Sep 27, 2023

Athersys, Inc. Appoints Joseph Nolan to Its Board of Directors

CEO, Secretary recently bought US$55k worth of stock

Recent updates

Motion For Case Conversion Approved for Athersys, Inc.

Motion for Case Conversion Filed by Athersys, Inc.

Healios K.K. (TSE:4593) completed the acquisition of Substantially all assets of Abt Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC .

Motion for Joint Administration Filed by Athersys, Inc.

Athersys, Inc. Announces Termination of Daniel A. Camardo as Chief Executive Officer, Effective from December 31, 2023

Athersys, Inc. announced delayed 10-Q filing

Athersys, Inc.(OTCPK:ATHX) dropped from S&P TMI Index

Athersys, Inc. Receives A Delisting Determination Letter from Nasdaq

Athersys, Inc. Reports Interim Analysis Results of MASTERS-2 Clinical Study with Multistem in Ischemic Stroke

Athersys, Inc. Appoints Jane Wasman as Board Chair

Athersys, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million.

Athersys, Inc. announced delayed 10-Q filing

Athersys, Inc. Appoints Neema Mayhugh to Its Board of Directors, Nominations, Governance and Compliance Committee, Compensation Committee and Audit Committee

New major risk - Market cap size

Athersys Receives Written Notice from Nasdaq Regarding Non-Compliance with Minimum Closing Bid Price Requirement

Athersys, Inc., Annual General Meeting, Sep 27, 2023

Athersys, Inc. Announces Patient Enrollment Begins in Third and Final Cohort of the Phase 2 Matrics-1 Clinical Study Evaluating Athersys' Multistem Following Hemorrhagic Trauma

Athersys Granted Clinical Type B Meeting with FDA for Masters-2 Clinical Trial Protocol Discussion

Athersys, Inc. Provides an Update on Ongoing Clinical Trials with MultiStem for the Treatment of Patients Following Hemorrhagic Trauma (MATRICS-1) and for the Treatment of Ischemic Stroke (MASTERS-2)

Athersys, Inc. Appoints Joseph Nolan to Its Board of Directors

CEO, Secretary recently bought US$55k worth of stock

Athersys: Is Big Pharma Sleeping At The Wheel?

Athersys extends exercise period of warrants in connection with recent offering

Athersys announces 1-for-25 reverse stock split

One Analyst's Revenue Estimates For Athersys, Inc. (NASDAQ:ATHX) Are Surging Higher

Athersys stock falls ~9% after reporting Q2 loss, fall in cash and cash equivalents

Kasey Rosado named interim CFO of Athersys

Athersys: Dead Man Walking

Consensus forecasts updated

Athersys: Focus On Stroke

Price target decreased to US$3.33

Athersys - Hero Or Zero Opportunity

Consensus revenue estimates fall by 70%

Price target decreased to US$3.33

Consensus forecasts updated

Price target increased to US$5.00

Athersys: Near-Term Progress In Stem Cell Phase 3 Trials Could Multiply Shares In 2022

Here's Why Athersys (NASDAQ:ATHX) Must Use Its Cash Wisely

Athersys: COVID-ARDS Is The Company's Most Important Target

Price target decreased to US$3.75

Third quarter 2021 earnings released: US$0.071 loss per share (vs US$0.11 loss in 3Q 2020)

Price target decreased to US$4.67

Athersys Shares Are Ready To Rumble Following Period Of Turmoil

Consensus forecasts updated

Consensus forecasts updated

Athersys: Subgroup Analysis As A Masterstroke

Here's Why We're Watching Athersys' (NASDAQ:ATHX) Cash Burn Situation

Consensus revenue estimates fall to US$9.42m

Full year 2020 earnings released: US$0.42 loss per share (vs US$0.29 loss in FY 2019)

Is Athersys (NASDAQ:ATHX) In A Good Position To Invest In Growth?

New 90-day high: US$2.44

New 90-day high: US$2.24

New 90-day low: US$1.55

Analysts lower revenue estimates to US$281.5k

Earnings beat expectations, revenue disappoints

New 90-day low: US$1.79

AMMINISTRATORE DELEGATO

Gruppo dirigente

Durata media

Analisi aziendale e situazione dei dati finanziari

Fonti dei dati

Modello di analisi e Snowflake

Metriche di settore e industriali

Fonti analitiche